Register Login

Recursion Pharmaceuticals Inc (RXRX)

  • Event
  • June 21, 2022, 12:04 UTC

(80% Positive) RECURSION PHARMACEUTICALS, INC. (RXRX) Announces Enrollment Update for designations Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 8:27 a.m.

    📋 RECURSION PHARMACEUTICALS, INC. (RXRX) - Clinical Trial Update

    Filing Date: 2022-06-21

    Accepted: 2022-06-21 08:04:58

    Event Type: Clinical Trial Update

    Event Details:

    Recursion Pharmaceuticals Inc (RXRX) Announces Clinical Trial Update Recursion Pharmaceuticals Inc (RXRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: designations, tumors
    • Diseases/Conditions: NF2-mutated meningiomas, approximately 33
    • Clinical Stage: Phase 2, clinical trial
    • Collaboration: Exhibit 99.1 Recursion Announces Initiation of Phase 2/3 Trial

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Recursion Pharmaceuticals Inc
    • CIK: 0001601830
    • Ticker Symbol: RXRX
    • Period End Date: 2022-06-20
    • Document Type: 8-K

Search

News categories